JP2009542679A5 - - Google Patents

Info

Publication number

JP2009542679A5

JP2009542679A5 JP2009518321A JP2009518321A JP2009542679A5 JP 2009542679 A5 JP2009542679 A5 JP 2009542679A5 JP 2009518321 A JP2009518321 A JP 2009518321A JP 2009518321 A JP2009518321 A JP 2009518321A JP 2009542679 A5 JP2009542679 A5 JP 2009542679A5

Authority

JP

Japan

Prior art keywords

alkyl

aryl

oso

opo

src

Prior art date

2007-06-29

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims description 322
• 229910052739 hydrogen Inorganic materials 0.000 claims description 196
• 125000003118 aryl group Chemical group 0.000 claims description 152
• 125000000217 alkyl group Chemical group 0.000 claims description 133
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 131
• 229930182470 glycoside Natural products 0.000 claims description 129
• 150000002338 glycosides Chemical class 0.000 claims description 129
• 125000000623 heterocyclic group Chemical group 0.000 claims description 80
• 150000005347 biaryls Chemical group 0.000 claims description 78
• 125000001072 heteroaryl group Chemical group 0.000 claims description 77
• 229910052736 halogen Inorganic materials 0.000 claims description 63
• 150000002367 halogens Chemical class 0.000 claims description 58
• -1 heteroaryl biaryl Chemical group 0.000 claims description 57
• 239000003814 drug Substances 0.000 claims description 55
• 208000006011 Stroke Diseases 0.000 claims description 49
• 229910052698 phosphorus Inorganic materials 0.000 claims description 48
• 150000005363 heterobiaryls Chemical group 0.000 claims description 40
• 238000004519 manufacturing process Methods 0.000 claims description 39
• 229910052799 carbon Inorganic materials 0.000 claims description 36
• 125000004122 cyclic group Chemical group 0.000 claims description 36
• 208000002672 hepatitis B Diseases 0.000 claims description 33
• 208000004296 neuralgia Diseases 0.000 claims description 31
• 208000021722 neuropathic pain Diseases 0.000 claims description 30
• 208000001132 Osteoporosis Diseases 0.000 claims description 29
• 238000011282 treatment Methods 0.000 claims description 29
• 206010011878 Deafness Diseases 0.000 claims description 26
• 230000010370 hearing loss Effects 0.000 claims description 26
• 231100000888 hearing loss Toxicity 0.000 claims description 26
• 208000016354 hearing loss disease Diseases 0.000 claims description 26
• 229910052796 boron Inorganic materials 0.000 claims description 25
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 24
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
• 208000008589 Obesity Diseases 0.000 claims description 21
• 235000020824 obesity Nutrition 0.000 claims description 21
• 201000001320 Atherosclerosis Diseases 0.000 claims description 20
• 229940002612 prodrug Drugs 0.000 claims description 19
• 239000000651 prodrug Substances 0.000 claims description 19
• 150000003839 salts Chemical class 0.000 claims description 19
• 239000012453 solvate Substances 0.000 claims description 19
• 101100240523 Caenorhabditis elegans nhr-19 gene Proteins 0.000 claims description 18
• 206010012601 diabetes mellitus Diseases 0.000 claims description 17
• 229910052717 sulfur Inorganic materials 0.000 claims description 17
• 238000001361 intraarterial administration Methods 0.000 claims description 16
• 238000007912 intraperitoneal administration Methods 0.000 claims description 16
• 239000003937 drug carrier Substances 0.000 claims description 15
• 238000007918 intramuscular administration Methods 0.000 claims description 15
• 238000001990 intravenous administration Methods 0.000 claims description 15
• 238000007920 subcutaneous administration Methods 0.000 claims description 15
• 230000000699 topical effect Effects 0.000 claims description 14
• 210000004877 mucosa Anatomy 0.000 claims description 13
• 230000002062 proliferating effect Effects 0.000 claims description 13
• 208000035475 disorder Diseases 0.000 claims description 11
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 10
• 230000002265 prevention Effects 0.000 claims description 10
• 208000030533 eye disease Diseases 0.000 claims description 9
• 238000001802 infusion Methods 0.000 claims description 5
• 239000008194 pharmaceutical composition Substances 0.000 claims description 5
• 125000000896 monocarboxylic acid group Chemical group 0.000 claims 12
• 239000003112 inhibitor Substances 0.000 description 203
• 101150001535 SRC gene Proteins 0.000 description 170
• 102000001253 Protein Kinase Human genes 0.000 description 123
• 108060006633 protein kinase Proteins 0.000 description 123
• 108090000765 processed proteins & peptides Proteins 0.000 description 104
• 230000000694 effects Effects 0.000 description 100
• 210000004027 cell Anatomy 0.000 description 91
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 90
• 230000027455 binding Effects 0.000 description 86
• 238000000034 method Methods 0.000 description 85
• YGGXZTQSGNFKPJ-UHFFFAOYSA-N methyl 2-naphthalen-1-ylacetate Chemical compound C1=CC=C2C(CC(=O)OC)=CC=CC2=C1 YGGXZTQSGNFKPJ-UHFFFAOYSA-N 0.000 description 78
• 239000000758 substrate Substances 0.000 description 68
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 61
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 59
• 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 51
• 238000003556 assay Methods 0.000 description 51
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 50
• 230000019491 signal transduction Effects 0.000 description 50
• 108091000080 Phosphotransferase Proteins 0.000 description 49
• 102000020233 phosphotransferase Human genes 0.000 description 49
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 45
• 125000000524 functional group Chemical group 0.000 description 43
• 150000001408 amides Chemical class 0.000 description 42
• 230000003197 catalytic effect Effects 0.000 description 42
• 230000005764 inhibitory process Effects 0.000 description 39
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 38
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 30
• 210000003477 cochlea Anatomy 0.000 description 29
• 208000024891 symptom Diseases 0.000 description 28
• 108010001127 Insulin Receptor Proteins 0.000 description 27
• 102000003746 Insulin Receptor Human genes 0.000 description 26
• 230000001965 increasing effect Effects 0.000 description 26
• 210000002997 osteoclast Anatomy 0.000 description 26
• 230000002633 protecting effect Effects 0.000 description 26
• 108090000623 proteins and genes Proteins 0.000 description 26
• 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 25
• 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 25
• 230000003993 interaction Effects 0.000 description 25
• 229940043355 kinase inhibitor Drugs 0.000 description 24
• 230000015572 biosynthetic process Effects 0.000 description 23
• 102000004169 proteins and genes Human genes 0.000 description 23
• 102000001332 SRC Human genes 0.000 description 22
• 108060006706 SRC Proteins 0.000 description 22
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 22
• 235000018102 proteins Nutrition 0.000 description 22
• 241000700112 Chinchilla Species 0.000 description 21
• 102000004190 Enzymes Human genes 0.000 description 21
• 108090000790 Enzymes Proteins 0.000 description 21
• 229940122924 Src inhibitor Drugs 0.000 description 21
• 230000002860 competitive effect Effects 0.000 description 21
• 229940088598 enzyme Drugs 0.000 description 21
• 238000002474 experimental method Methods 0.000 description 21
• 239000001257 hydrogen Substances 0.000 description 21
• 102000004877 Insulin Human genes 0.000 description 19
• 108090001061 Insulin Proteins 0.000 description 19
• 229940125396 insulin Drugs 0.000 description 19
• 229910052757 nitrogen Inorganic materials 0.000 description 19
• 125000001624 naphthyl group Chemical group 0.000 description 18
• 206010028980 Neoplasm Diseases 0.000 description 17
• ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 17
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 17
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 17
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 17
• 229940125528 allosteric inhibitor Drugs 0.000 description 17
• 230000001413 cellular effect Effects 0.000 description 17
• 230000026731 phosphorylation Effects 0.000 description 17
• 238000006366 phosphorylation reaction Methods 0.000 description 17
• 239000003909 protein kinase inhibitor Substances 0.000 description 17
• 230000011664 signaling Effects 0.000 description 17
• 238000012360 testing method Methods 0.000 description 17
• 238000006243 chemical reaction Methods 0.000 description 16
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 16
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 16
• 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 15
• 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 15
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 15
• 229910019142 PO4 Inorganic materials 0.000 description 15
• 210000001367 artery Anatomy 0.000 description 15
• 125000001041 indolyl group Chemical group 0.000 description 15
• 239000010452 phosphate Substances 0.000 description 15
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 15
• HUNGUWOZPQBXGX-UHFFFAOYSA-N tirbanibulin Chemical compound C=1C=CC=CC=1CNC(=O)CC(N=C1)=CC=C1C(C=C1)=CC=C1OCCN1CCOCC1 HUNGUWOZPQBXGX-UHFFFAOYSA-N 0.000 description 15
• 230000006378 damage Effects 0.000 description 14
• 229940079593 drug Drugs 0.000 description 14
• 230000008569 process Effects 0.000 description 14
• 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 13
• 238000011161 development Methods 0.000 description 13
• 230000018109 developmental process Effects 0.000 description 13
• 102000009076 src-Family Kinases Human genes 0.000 description 13
• 108010087686 src-Family Kinases Proteins 0.000 description 13
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 12
• 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 12
• 230000004913 activation Effects 0.000 description 12
• 210000004556 brain Anatomy 0.000 description 12
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 12
• 238000013461 design Methods 0.000 description 12
• 230000006870 function Effects 0.000 description 12
• 230000002209 hydrophobic effect Effects 0.000 description 12
• 208000010125 myocardial infarction Diseases 0.000 description 12
• LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 12
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 11
• 241000699670 Mus sp. Species 0.000 description 11
• 241000700605 Viruses Species 0.000 description 11
• 239000000427 antigen Substances 0.000 description 11
• 108091007433 antigens Proteins 0.000 description 11
• 102000036639 antigens Human genes 0.000 description 11
• 125000005620 boronic acid group Chemical group 0.000 description 11
• 235000013877 carbamide Nutrition 0.000 description 11
• 201000010099 disease Diseases 0.000 description 11
• ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 11
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 10
• SVSKFMJQWMZCRD-MCDZGGTQSA-L MgADP Chemical compound [Mg+2].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP(O)([O-])=O)[C@@H](O)[C@H]1O SVSKFMJQWMZCRD-MCDZGGTQSA-L 0.000 description 10
• 208000007536 Thrombosis Diseases 0.000 description 10
• 230000035578 autophosphorylation Effects 0.000 description 10
• 210000004369 blood Anatomy 0.000 description 10
• 239000008280 blood Substances 0.000 description 10
• 239000004202 carbamide Substances 0.000 description 10
• 150000001733 carboxylic acid esters Chemical class 0.000 description 10
• AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 10
• 125000005842 heteroatom Chemical group 0.000 description 10
• 208000015181 infectious disease Diseases 0.000 description 10
• 229940043437 protein kinase A inhibitor Drugs 0.000 description 10
• 230000002829 reductive effect Effects 0.000 description 10
• 238000012216 screening Methods 0.000 description 10
• 238000006467 substitution reaction Methods 0.000 description 10
• 150000003568 thioethers Chemical class 0.000 description 10
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 10
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 10
• 208000023275 Autoimmune disease Diseases 0.000 description 9
• 208000006386 Bone Resorption Diseases 0.000 description 9
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 9
• 108091007960 PI3Ks Proteins 0.000 description 9
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 9
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 9
• 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 9
• 208000027418 Wounds and injury Diseases 0.000 description 9
• 150000001412 amines Chemical class 0.000 description 9
• 210000004204 blood vessel Anatomy 0.000 description 9
• 230000024279 bone resorption Effects 0.000 description 9
• 230000010261 cell growth Effects 0.000 description 9
• 230000001684 chronic effect Effects 0.000 description 9
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 9
• 230000012010 growth Effects 0.000 description 9
• 230000002401 inhibitory effect Effects 0.000 description 9
• 208000014674 injury Diseases 0.000 description 9
• 239000011777 magnesium Substances 0.000 description 9
• 150000003457 sulfones Chemical class 0.000 description 9
• 150000003462 sulfoxides Chemical class 0.000 description 9
• 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 9
• 208000002193 Pain Diseases 0.000 description 8
• 239000000370 acceptor Substances 0.000 description 8
• 125000003545 alkoxy group Chemical group 0.000 description 8
• 230000017531 blood circulation Effects 0.000 description 8
• 125000004432 carbon atom Chemical group C* 0.000 description 8
• 239000013078 crystal Substances 0.000 description 8
• 150000002391 heterocyclic compounds Chemical class 0.000 description 8
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 8
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 8
• 230000003834 intracellular effect Effects 0.000 description 8
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 8
• 238000000021 kinase assay Methods 0.000 description 8
• 229910052760 oxygen Inorganic materials 0.000 description 8
• 239000001301 oxygen Substances 0.000 description 8
• 230000037361 pathway Effects 0.000 description 8
• 239000003934 phosphoprotein phosphatase inhibitor Substances 0.000 description 8
• 230000004044 response Effects 0.000 description 8
• 229960001153 serine Drugs 0.000 description 8
• 230000001225 therapeutic effect Effects 0.000 description 8
• 210000001519 tissue Anatomy 0.000 description 8
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 8
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
• 102000001301 EGF receptor Human genes 0.000 description 7
• 108060006698 EGF receptor Proteins 0.000 description 7
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
• YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 7
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 7
• 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 7
• 230000006907 apoptotic process Effects 0.000 description 7
• 125000004429 atom Chemical group 0.000 description 7
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
• 210000000988 bone and bone Anatomy 0.000 description 7
• 230000007423 decrease Effects 0.000 description 7
• 150000002148 esters Chemical class 0.000 description 7
• 229910052731 fluorine Inorganic materials 0.000 description 7
• 239000011737 fluorine Substances 0.000 description 7
• 230000014509 gene expression Effects 0.000 description 7
• 125000005843 halogen group Chemical group 0.000 description 7
• 208000002780 macular degeneration Diseases 0.000 description 7
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• 238000012546 transfer Methods 0.000 description 7
• XXCSQHMDTJAWNX-PVKGJVGDSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s,3r)-1-[[(2s)-1-[[(2s)-4-amino-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]- Chemical compound N([C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CO)C(N)=O)[C@@H](C)O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN XXCSQHMDTJAWNX-PVKGJVGDSA-N 0.000 description 6
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
• 208000005189 Embolism Diseases 0.000 description 6
• 241000700721 Hepatitis B virus Species 0.000 description 6
• 101000688606 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 Proteins 0.000 description 6
• 102100024242 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 Human genes 0.000 description 6
• 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 6
• 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 6
• 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 6
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
• 108091008874 T cell receptors Proteins 0.000 description 6
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 150000001299 aldehydes Chemical class 0.000 description 6
• 239000003146 anticoagulant agent Substances 0.000 description 6
• 239000002246 antineoplastic agent Substances 0.000 description 6
• 230000033228 biological regulation Effects 0.000 description 6
• 238000010586 diagram Methods 0.000 description 6
• 208000037765 diseases and disorders Diseases 0.000 description 6
• 230000004190 glucose uptake Effects 0.000 description 6
• 229930182478 glucoside Natural products 0.000 description 6
• 150000008131 glucosides Chemical class 0.000 description 6
• 210000002216 heart Anatomy 0.000 description 6
• 239000003446 ligand Substances 0.000 description 6
• 150000003008 phosphonic acid esters Chemical class 0.000 description 6
• 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 6
• 102000005962 receptors Human genes 0.000 description 6
• 108020003175 receptors Proteins 0.000 description 6
• 230000000638 stimulation Effects 0.000 description 6
• 230000004083 survival effect Effects 0.000 description 6
• 230000008728 vascular permeability Effects 0.000 description 6
• HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 5
• 206010008479 Chest Pain Diseases 0.000 description 5
• 206010011903 Deafness traumatic Diseases 0.000 description 5
• 108010091824 Focal Adhesion Kinase 1 Proteins 0.000 description 5
• 102100037813 Focal adhesion kinase 1 Human genes 0.000 description 5
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 5
• 208000002946 Noise-Induced Hearing Loss Diseases 0.000 description 5
• 208000022873 Ocular disease Diseases 0.000 description 5
• 229940116193 Protein phosphatase inhibitor Drugs 0.000 description 5
• 210000001744 T-lymphocyte Anatomy 0.000 description 5
• 206010043647 Thrombotic Stroke Diseases 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• 150000008064 anhydrides Chemical class 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 201000011510 cancer Diseases 0.000 description 5
• 239000003054 catalyst Substances 0.000 description 5
• 239000007795 chemical reaction product Substances 0.000 description 5
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
• 229960004316 cisplatin Drugs 0.000 description 5
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 5
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
• 238000011156 evaluation Methods 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 230000001404 mediated effect Effects 0.000 description 5
• 210000000963 osteoblast Anatomy 0.000 description 5
• UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 5
• 230000001105 regulatory effect Effects 0.000 description 5
• 238000002560 therapeutic procedure Methods 0.000 description 5
• 210000004881 tumor cell Anatomy 0.000 description 5
• 230000003612 virological effect Effects 0.000 description 5
• PVKSNHVPLWYQGJ-KQYNXXCUSA-N AMP-PNP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)NP(O)(O)=O)[C@@H](O)[C@H]1O PVKSNHVPLWYQGJ-KQYNXXCUSA-N 0.000 description 4
• 241000700199 Cavia porcellus Species 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• 206010014498 Embolic stroke Diseases 0.000 description 4
• 208000032843 Hemorrhage Diseases 0.000 description 4
• 206010061216 Infarction Diseases 0.000 description 4
• 208000032382 Ischaemic stroke Diseases 0.000 description 4
• 208000001344 Macular Edema Diseases 0.000 description 4
• 206010025415 Macular oedema Diseases 0.000 description 4
• 206010029113 Neovascularisation Diseases 0.000 description 4
• 108091008606 PDGF receptors Proteins 0.000 description 4
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 4
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 4
• 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 4
• 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 4
• 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 4
• 208000017442 Retinal disease Diseases 0.000 description 4
• 208000034189 Sclerosis Diseases 0.000 description 4
• 108010026479 Src peptide Proteins 0.000 description 4
• 206010052779 Transplant rejections Diseases 0.000 description 4
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 4
• ZSZXYWFCIKKZBT-ZVDPZPSOSA-N [(2r)-3-[[(2s,3s,5r,6s)-2,6-dihydroxy-3,4,5-triphosphonooxycyclohexyl]oxy-hydroxyphosphoryl]oxy-2-hexadecanoyloxypropyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OC1[C@H](O)[C@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O ZSZXYWFCIKKZBT-ZVDPZPSOSA-N 0.000 description 4
• 206010003119 arrhythmia Diseases 0.000 description 4
• 230000006793 arrhythmia Effects 0.000 description 4
• 239000004305 biphenyl Substances 0.000 description 4
• 235000010290 biphenyl Nutrition 0.000 description 4
• 230000000740 bleeding effect Effects 0.000 description 4
• 150000001735 carboxylic acids Chemical class 0.000 description 4
• 230000004663 cell proliferation Effects 0.000 description 4
• 230000002490 cerebral effect Effects 0.000 description 4
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
• WUVFAMRFBRHSQW-UHFFFAOYSA-N chromen-2-imine Chemical group C1=CC=C2OC(=N)C=CC2=C1 WUVFAMRFBRHSQW-UHFFFAOYSA-N 0.000 description 4
• 238000010168 coupling process Methods 0.000 description 4
• 238000005859 coupling reaction Methods 0.000 description 4
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 230000004069 differentiation Effects 0.000 description 4
• 210000002768 hair cell Anatomy 0.000 description 4
• 230000005965 immune activity Effects 0.000 description 4
• 230000006872 improvement Effects 0.000 description 4
• 230000007574 infarction Effects 0.000 description 4
• 230000003902 lesion Effects 0.000 description 4
• 150000002632 lipids Chemical class 0.000 description 4
• 201000010230 macular retinal edema Diseases 0.000 description 4
• 239000011159 matrix material Substances 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 210000004379 membrane Anatomy 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 238000013508 migration Methods 0.000 description 4
• 210000005036 nerve Anatomy 0.000 description 4
• 238000011275 oncology therapy Methods 0.000 description 4
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
• 150000003905 phosphatidylinositols Chemical class 0.000 description 4
• 229940080469 phosphocellulose Drugs 0.000 description 4
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
• 239000000047 product Substances 0.000 description 4
• 239000012656 protein kinase A inhibitor Substances 0.000 description 4
• 108010065251 protein kinase modulator Proteins 0.000 description 4
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 4
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 4
• 239000011347 resin Substances 0.000 description 4
• 229920005989 resin Polymers 0.000 description 4
• 230000009885 systemic effect Effects 0.000 description 4
• 238000002604 ultrasonography Methods 0.000 description 4
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
• 206010065687 Bone loss Diseases 0.000 description 3
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• 108020004414 DNA Proteins 0.000 description 3
• 206010012689 Diabetic retinopathy Diseases 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 206010058558 Hypoperfusion Diseases 0.000 description 3
• 206010022489 Insulin Resistance Diseases 0.000 description 3
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
• 208000001294 Nociceptive Pain Diseases 0.000 description 3
• 108700020796 Oncogene Proteins 0.000 description 3
• 206010061535 Ovarian neoplasm Diseases 0.000 description 3
• 101710188315 Protein X Proteins 0.000 description 3
• 102000004903 Troponin Human genes 0.000 description 3
• 108090001027 Troponin Proteins 0.000 description 3
• 108091008605 VEGF receptors Proteins 0.000 description 3
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 230000005856 abnormality Effects 0.000 description 3
• 150000001298 alcohols Chemical class 0.000 description 3
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
• 125000003368 amide group Chemical group 0.000 description 3
• 230000033115 angiogenesis Effects 0.000 description 3
• 229940127219 anticoagulant drug Drugs 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 230000036772 blood pressure Effects 0.000 description 3
• 230000000747 cardiac effect Effects 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 230000001886 ciliary effect Effects 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• 239000007771 core particle Substances 0.000 description 3
• 230000008878 coupling Effects 0.000 description 3
• 210000004292 cytoskeleton Anatomy 0.000 description 3
• 230000001086 cytosolic effect Effects 0.000 description 3
• 230000007547 defect Effects 0.000 description 3
• 230000007812 deficiency Effects 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• 125000005265 dialkylamine group Chemical group 0.000 description 3
• 210000001508 eye Anatomy 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 208000006454 hepatitis Diseases 0.000 description 3
• 238000011905 homologation Methods 0.000 description 3
• GTTBQSNGUYHPNK-UHFFFAOYSA-N hydroxymethylphosphonic acid Chemical compound OCP(O)(O)=O GTTBQSNGUYHPNK-UHFFFAOYSA-N 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 230000000977 initiatory effect Effects 0.000 description 3
• 239000000543 intermediate Substances 0.000 description 3
• 230000000302 ischemic effect Effects 0.000 description 3
• 108010046629 kemptamide Proteins 0.000 description 3
• 125000005647 linker group Chemical group 0.000 description 3
• 108020004999 messenger RNA Proteins 0.000 description 3
• 230000004060 metabolic process Effects 0.000 description 3
• 230000005012 migration Effects 0.000 description 3
• 238000000324 molecular mechanic Methods 0.000 description 3
• 238000000302 molecular modelling Methods 0.000 description 3
• LVCDXCQFSONNDO-UHFFFAOYSA-N n-benzylhydroxylamine Chemical compound ONCC1=CC=CC=C1 LVCDXCQFSONNDO-UHFFFAOYSA-N 0.000 description 3
• 239000006225 natural substrate Substances 0.000 description 3
• 210000004126 nerve fiber Anatomy 0.000 description 3
• 239000012038 nucleophile Substances 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 230000011164 ossification Effects 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• 208000035824 paresthesia Diseases 0.000 description 3
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
• 229920001296 polysiloxane Polymers 0.000 description 3
• 230000003389 potentiating effect Effects 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 102000004196 processed proteins & peptides Human genes 0.000 description 3
• 108010060709 protein kinase inhibitor peptide (5-24) Proteins 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 238000010839 reverse transcription Methods 0.000 description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 239000007790 solid phase Substances 0.000 description 3
• 108700026239 src Genes Proteins 0.000 description 3
• 238000010186 staining Methods 0.000 description 3
• 238000005556 structure-activity relationship Methods 0.000 description 3
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 3
• 238000010189 synthetic method Methods 0.000 description 3
• 230000008685 targeting Effects 0.000 description 3
• 231100000331 toxic Toxicity 0.000 description 3
• 230000002588 toxic effect Effects 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 3
• BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 2
• IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical group C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
• FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
• BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 2
• YELLAPKUWRTITI-UHFFFAOYSA-N 3,5-dihydroxynaphthalene-2-carboxylic acid Chemical compound C1=CC(O)=C2C=C(O)C(C(=O)O)=CC2=C1 YELLAPKUWRTITI-UHFFFAOYSA-N 0.000 description 2
• TUIHIKXCMCXXJG-UHFFFAOYSA-N 5-fluoro-n-[(3-hydroxyphenyl)methyl]-1h-indole-2-carboxamide Chemical compound OC1=CC=CC(CNC(=O)C=2NC3=CC=C(F)C=C3C=2)=C1 TUIHIKXCMCXXJG-UHFFFAOYSA-N 0.000 description 2
• IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
• 206010002329 Aneurysm Diseases 0.000 description 2
• 208000020084 Bone disease Diseases 0.000 description 2
• 206010048962 Brain oedema Diseases 0.000 description 2
• 101710132601 Capsid protein Proteins 0.000 description 2
• 102000003952 Caspase 3 Human genes 0.000 description 2
• 108090000397 Caspase 3 Proteins 0.000 description 2
• 206010008190 Cerebrovascular accident Diseases 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
• 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
• 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
• 208000000059 Dyspnea Diseases 0.000 description 2
• 206010013975 Dyspnoeas Diseases 0.000 description 2
• 101710091045 Envelope protein Proteins 0.000 description 2
• 102400001368 Epidermal growth factor Human genes 0.000 description 2
• 101800003838 Epidermal growth factor Proteins 0.000 description 2
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
• 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• 102000007390 Glycogen Phosphorylase Human genes 0.000 description 2
• 108010046163 Glycogen Phosphorylase Proteins 0.000 description 2
• 102000009465 Growth Factor Receptors Human genes 0.000 description 2
• 108010009202 Growth Factor Receptors Proteins 0.000 description 2
• 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 2
• 208000016988 Hemorrhagic Stroke Diseases 0.000 description 2
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
• 101000616502 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Proteins 0.000 description 2
• 102100034349 Integrase Human genes 0.000 description 2
• 206010023230 Joint stiffness Diseases 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 2
• 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
• 206010067125 Liver injury Diseases 0.000 description 2
• 108010002481 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Proteins 0.000 description 2
• 102000036243 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Human genes 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• 208000007101 Muscle Cramp Diseases 0.000 description 2
• 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
• 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
• LQQYARMJQBHKQQ-UHFFFAOYSA-N N-[3-chloro-4-[(6-methoxypyrazolo[1,5-a]pyridine-3-carbonyl)amino]phenyl]-1-[1-(3-cyano-3-methylbutanoyl)piperidin-4-yl]-5-fluoroindazole-3-carboxamide Chemical compound COc1ccc2c(cnn2c1)C(=O)Nc1ccc(NC(=O)c2nn(C3CCN(CC3)C(=O)CC(C)(C)C#N)c3ccc(F)cc23)cc1Cl LQQYARMJQBHKQQ-UHFFFAOYSA-N 0.000 description 2
• 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 2
• 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 2
• BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 2
• 108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 2
• 229930012538 Paclitaxel Natural products 0.000 description 2
• 102000018546 Paxillin Human genes 0.000 description 2
• ACNHBCIZLNNLRS-UHFFFAOYSA-N Paxilline 1 Natural products N1C2=CC=CC=C2C2=C1C1(C)C3(C)CCC4OC(C(C)(O)C)C(=O)C=C4C3(O)CCC1C2 ACNHBCIZLNNLRS-UHFFFAOYSA-N 0.000 description 2
• 102100021797 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Human genes 0.000 description 2
• IIXHQGSINFQLRR-UHFFFAOYSA-N Piceatannol Natural products Oc1ccc(C=Cc2c(O)c(O)c3CCCCc3c2O)cc1O IIXHQGSINFQLRR-UHFFFAOYSA-N 0.000 description 2
• 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 2
• 108010015730 Proto-Oncogene Proteins pp60(c-src) Proteins 0.000 description 2
• 102000002007 Proto-Oncogene Proteins pp60(c-src) Human genes 0.000 description 2
• 108091006300 SLC2A4 Proteins 0.000 description 2
• 108020004459 Small interfering RNA Proteins 0.000 description 2
• 108700031954 Tgfb1i1/Leupaxin/TGFB1I1 Proteins 0.000 description 2
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
• 206010047700 Vomiting Diseases 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 238000009825 accumulation Methods 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 206010000891 acute myocardial infarction Diseases 0.000 description 2
• 210000005006 adaptive immune system Anatomy 0.000 description 2
• 238000007792 addition Methods 0.000 description 2
• 210000001789 adipocyte Anatomy 0.000 description 2
• 206010064930 age-related macular degeneration Diseases 0.000 description 2
• 150000001336 alkenes Chemical class 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 229940024606 amino acid Drugs 0.000 description 2
• 235000001014 amino acid Nutrition 0.000 description 2
• 150000001413 amino acids Chemical class 0.000 description 2
• 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 2
• 238000002583 angiography Methods 0.000 description 2
• 230000000702 anti-platelet effect Effects 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 230000003078 antioxidant effect Effects 0.000 description 2
• 235000006708 antioxidants Nutrition 0.000 description 2
• 230000009925 apoptotic mechanism Effects 0.000 description 2
• 150000001502 aryl halides Chemical class 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 239000002585 base Substances 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 125000001743 benzylic group Chemical group 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 238000009534 blood test Methods 0.000 description 2
• 150000001642 boronic acid derivatives Chemical class 0.000 description 2
• 208000006752 brain edema Diseases 0.000 description 2
• 238000004364 calculation method Methods 0.000 description 2
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
• 125000002091 cationic group Chemical group 0.000 description 2
• 230000003915 cell function Effects 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 210000001627 cerebral artery Anatomy 0.000 description 2
• 208000026106 cerebrovascular disease Diseases 0.000 description 2
• 239000003795 chemical substances by application Substances 0.000 description 2
• 210000000038 chest Anatomy 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 239000002131 composite material Substances 0.000 description 2
• 238000002591 computed tomography Methods 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 210000004351 coronary vessel Anatomy 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 238000004807 desolvation Methods 0.000 description 2
• 229950006137 dexfosfoserine Drugs 0.000 description 2
• ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 2
• 235000005911 diet Nutrition 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• 230000010339 dilation Effects 0.000 description 2
• 208000002173 dizziness Diseases 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 239000006196 drop Substances 0.000 description 2
• 229940000406 drug candidate Drugs 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 230000037149 energy metabolism Effects 0.000 description 2
• 229940116977 epidermal growth factor Drugs 0.000 description 2
• IFMOTUDBXOSDHR-UHFFFAOYSA-N ethyl 2-[(2-bromo-4-fluorophenyl)hydrazinylidene]propanoate Chemical compound CCOC(=O)C(C)=NNC1=CC=C(F)C=C1Br IFMOTUDBXOSDHR-UHFFFAOYSA-N 0.000 description 2
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
• 229960005420 etoposide Drugs 0.000 description 2
• 210000002744 extracellular matrix Anatomy 0.000 description 2
• 230000002349 favourable effect Effects 0.000 description 2
• 239000003527 fibrinolytic agent Substances 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 239000012467 final product Substances 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 230000009036 growth inhibition Effects 0.000 description 2
• 231100000234 hepatic damage Toxicity 0.000 description 2
• 210000003494 hepatocyte Anatomy 0.000 description 2
• 238000013537 high throughput screening Methods 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 150000004677 hydrates Chemical class 0.000 description 2
• 230000036571 hydration Effects 0.000 description 2
• 238000006703 hydration reaction Methods 0.000 description 2
• 229930195733 hydrocarbon Natural products 0.000 description 2
• 150000002430 hydrocarbons Chemical class 0.000 description 2
• 208000034783 hypoesthesia Diseases 0.000 description 2
• 208000026278 immune system disease Diseases 0.000 description 2
• 229960003444 immunosuppressant agent Drugs 0.000 description 2
• 239000003018 immunosuppressive agent Substances 0.000 description 2
• 150000002475 indoles Chemical class 0.000 description 2
• 229960000367 inositol Drugs 0.000 description 2
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
• 108010044426 integrins Proteins 0.000 description 2
• 102000006495 integrins Human genes 0.000 description 2
• 210000004692 intercellular junction Anatomy 0.000 description 2
• 230000002427 irreversible effect Effects 0.000 description 2
• 208000037906 ischaemic injury Diseases 0.000 description 2
• 238000009533 lab test Methods 0.000 description 2
• JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 230000008818 liver damage Effects 0.000 description 2
• 230000033001 locomotion Effects 0.000 description 2
• 206010025135 lupus erythematosus Diseases 0.000 description 2
• 238000002595 magnetic resonance imaging Methods 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 230000014399 negative regulation of angiogenesis Effects 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• 125000003729 nucleotide group Chemical group 0.000 description 2
• 210000004940 nucleus Anatomy 0.000 description 2
• 231100000862 numbness Toxicity 0.000 description 2
• 229960001592 paclitaxel Drugs 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• ACNHBCIZLNNLRS-UBGQALKQSA-N paxilline Chemical compound N1C2=CC=CC=C2C2=C1[C@]1(C)[C@@]3(C)CC[C@@H]4O[C@H](C(C)(O)C)C(=O)C=C4[C@]3(O)CC[C@H]1C2 ACNHBCIZLNNLRS-UBGQALKQSA-N 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 230000000865 phosphorylative effect Effects 0.000 description 2
• BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical group OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 2
• DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 2
• 229910052697 platinum Inorganic materials 0.000 description 2
• 238000011533 pre-incubation Methods 0.000 description 2
• PMXCMJLOPOFPBT-HNNXBMFYSA-N purvalanol A Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)C(C)C)=NC=1NC1=CC=CC(Cl)=C1 PMXCMJLOPOFPBT-HNNXBMFYSA-N 0.000 description 2
• 238000007634 remodeling Methods 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 230000002207 retinal effect Effects 0.000 description 2
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical group C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 230000001953 sensory effect Effects 0.000 description 2
• 210000002027 skeletal muscle Anatomy 0.000 description 2
• 239000004055 small Interfering RNA Substances 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 2
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 229960000103 thrombolytic agent Drugs 0.000 description 2
• RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
• 230000000451 tissue damage Effects 0.000 description 2
• 231100000827 tissue damage Toxicity 0.000 description 2
• 230000007704 transition Effects 0.000 description 2
• 102000027257 transmembrane receptors Human genes 0.000 description 2
• 108091008578 transmembrane receptors Proteins 0.000 description 2
• 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 2
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
• 210000003462 vein Anatomy 0.000 description 2
• 230000029812 viral genome replication Effects 0.000 description 2
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
• IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 1
• OZPPBQMEFADOEU-QAXPSLGGSA-N (4s)-4-[[2-[[(2s)-2-[[(2s,3s)-2-acetamido-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-5-oxopentanoic acid Chemical compound C([C@H](NC(=O)[C@@H](NC(C)=O)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=C(O)C=C1 OZPPBQMEFADOEU-QAXPSLGGSA-N 0.000 description 1
• UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
• USASUEYARBQNBM-UHFFFAOYSA-N 1h-indol-2-ylboronic acid Chemical compound C1=CC=C2NC(B(O)O)=CC2=C1 USASUEYARBQNBM-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
• MENAYYMPBRSAAE-AWEZNQCLSA-N 3-[[5-[[(2s)-1-carboxy-3-oxopropan-2-yl]carbamoyl]pyridin-2-yl]methylsulfamoyl]benzoic acid Chemical compound N1=CC(C(=O)N[C@@H](CC(=O)O)C=O)=CC=C1CNS(=O)(=O)C1=CC=CC(C(O)=O)=C1 MENAYYMPBRSAAE-AWEZNQCLSA-N 0.000 description 1
• CWLKGDAVCFYWJK-UHFFFAOYSA-N 3-aminophenol Chemical group NC1=CC=CC(O)=C1 CWLKGDAVCFYWJK-UHFFFAOYSA-N 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• NXAYYSHEARRBLR-UHFFFAOYSA-N 7-(3,5-diethyl-1-methylpyrazol-4-yl)-1-(2-morpholin-4-ylethyl)-3-(3-naphthalen-1-yloxypropyl)indole-2-carboxylic acid Chemical compound CCc1nn(C)c(CC)c1-c1cccc2c(CCCOc3cccc4ccccc34)c(C(O)=O)n(CCN3CCOCC3)c12 NXAYYSHEARRBLR-UHFFFAOYSA-N 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 102000006306 Antigen Receptors Human genes 0.000 description 1
• 108010083359 Antigen Receptors Proteins 0.000 description 1
• 102000004452 Arginase Human genes 0.000 description 1
• 108700024123 Arginases Proteins 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 206010003658 Atrial Fibrillation Diseases 0.000 description 1
• 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
• ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 102100028237 Breast cancer anti-estrogen resistance protein 1 Human genes 0.000 description 1
• 108050007340 Breast cancer anti-estrogen resistance protein 1 Proteins 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
• 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
• 208000000094 Chronic Pain Diseases 0.000 description 1
• 206010010144 Completed suicide Diseases 0.000 description 1
• 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
• 102000004420 Creatine Kinase Human genes 0.000 description 1
• 108010042126 Creatine kinase Proteins 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 102100034581 Dihydroorotase Human genes 0.000 description 1
• 108091000126 Dihydroorotase Proteins 0.000 description 1
• MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
• 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
• 108091008794 FGF receptors Proteins 0.000 description 1
• 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
• 108010091820 Focal Adhesion Kinase 2 Proteins 0.000 description 1
• 102000042092 Glucose transporter family Human genes 0.000 description 1
• 108091052347 Glucose transporter family Proteins 0.000 description 1
• 102000034575 Glutamate transporters Human genes 0.000 description 1
• 108091006151 Glutamate transporters Proteins 0.000 description 1
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• 208000010496 Heart Arrest Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
• 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 208000004044 Hypesthesia Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102000006940 Interleukin-1 Receptor-Associated Kinases Human genes 0.000 description 1
• 108010072621 Interleukin-1 Receptor-Associated Kinases Proteins 0.000 description 1
• 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
• 206010023126 Jaundice Diseases 0.000 description 1
• 101150088608 Kdr gene Proteins 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• 150000008575 L-amino acids Chemical class 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
• 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
• 206010024119 Left ventricular failure Diseases 0.000 description 1
• 239000002841 Lewis acid Substances 0.000 description 1
• 238000006219 Matteson homologation reaction Methods 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• 238000006751 Mitsunobu reaction Methods 0.000 description 1
• 208000034819 Mobility Limitation Diseases 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
• CKRZKMFTZCFYGB-UHFFFAOYSA-N N-phenylhydroxylamine Chemical compound ONC1=CC=CC=C1 CKRZKMFTZCFYGB-UHFFFAOYSA-N 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• HDQHFRDOKRVFDW-UHFFFAOYSA-N O.OBO Chemical class O.OBO HDQHFRDOKRVFDW-UHFFFAOYSA-N 0.000 description 1
• NNOZTDIONUPHDY-UHFFFAOYSA-N OBO.OP(O)=O Chemical compound OBO.OP(O)=O NNOZTDIONUPHDY-UHFFFAOYSA-N 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
• 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 201000010183 Papilledema Diseases 0.000 description 1
• 208000031481 Pathologic Constriction Diseases 0.000 description 1
• 208000037273 Pathologic Processes Diseases 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 101710106759 Protein-tyrosine kinase 2-beta Proteins 0.000 description 1
• 102000052575 Proto-Oncogene Human genes 0.000 description 1
• 108700020978 Proto-Oncogene Proteins 0.000 description 1
• 102100027384 Proto-oncogene tyrosine-protein kinase Src Human genes 0.000 description 1
• 101710122944 Proto-oncogene tyrosine-protein kinase Src Proteins 0.000 description 1
• 208000036741 Pruritus generalised Diseases 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 208000010378 Pulmonary Embolism Diseases 0.000 description 1
• 206010037368 Pulmonary congestion Diseases 0.000 description 1
• 206010037423 Pulmonary oedema Diseases 0.000 description 1
• 208000035977 Rare disease Diseases 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
• 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 208000007135 Retinal Neovascularization Diseases 0.000 description 1
• 206010038848 Retinal detachment Diseases 0.000 description 1
• 206010038886 Retinal oedema Diseases 0.000 description 1
• 206010038934 Retinopathy proliferative Diseases 0.000 description 1
• 102000038012 SFKs Human genes 0.000 description 1
• 108091008118 SFKs Proteins 0.000 description 1
• 102000029713 SH2 domain binding proteins Human genes 0.000 description 1
• 108091009286 SH2 domain binding proteins Proteins 0.000 description 1
• 102000014400 SH2 domains Human genes 0.000 description 1
• 108050003452 SH2 domains Proteins 0.000 description 1
• 102000033686 SH3 domain binding proteins Human genes 0.000 description 1
• 108091009674 SH3 domain binding proteins Proteins 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• 108010022999 Serine Proteases Proteins 0.000 description 1
• 102000012479 Serine Proteases Human genes 0.000 description 1
• 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 1
• 208000032023 Signs and Symptoms Diseases 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 108010023197 Streptokinase Proteins 0.000 description 1
• 108091027544 Subgenomic mRNA Proteins 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 206010043458 Thirst Diseases 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
• 208000003443 Unconsciousness Diseases 0.000 description 1
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
• 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
• 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
• 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
• 206010053649 Vascular rupture Diseases 0.000 description 1
• 239000003875 Wang resin Substances 0.000 description 1
• 101710086987 X protein Proteins 0.000 description 1
• 102100023870 YLP motif-containing protein 1 Human genes 0.000 description 1
• GVLOFRPVRYAFKI-VSGBNLITSA-N [(2R,5R)-2-benzyl-5-prop-2-ynoxypiperidin-1-yl]-[4-[bis(4-fluorophenyl)-hydroxymethyl]triazol-2-yl]methanone Chemical compound OC(c1cnn(n1)C(=O)N1C[C@@H](CC[C@@H]1Cc1ccccc1)OCC#C)(c1ccc(F)cc1)c1ccc(F)cc1 GVLOFRPVRYAFKI-VSGBNLITSA-N 0.000 description 1
• INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 1
• NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 229960004308 acetylcysteine Drugs 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 230000033289 adaptive immune response Effects 0.000 description 1
• 210000000593 adipose tissue white Anatomy 0.000 description 1
• 125000002877 alkyl aryl group Chemical group 0.000 description 1
• 230000003281 allosteric effect Effects 0.000 description 1
• 125000000746 allylic group Chemical group 0.000 description 1
• MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
• 229940124325 anabolic agent Drugs 0.000 description 1
• 239000003263 anabolic agent Substances 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 125000000129 anionic group Chemical group 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 210000003423 ankle Anatomy 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 230000002236 anti-hypertrophic effect Effects 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 239000003529 anticholesteremic agent Substances 0.000 description 1
• 229940127226 anticholesterol agent Drugs 0.000 description 1
• 229940125681 anticonvulsant agent Drugs 0.000 description 1
• 239000001961 anticonvulsive agent Substances 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 229940127218 antiplatelet drug Drugs 0.000 description 1
• 229960004676 antithrombotic agent Drugs 0.000 description 1
• 210000000709 aorta Anatomy 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 230000004596 appetite loss Effects 0.000 description 1
• 230000008321 arterial blood flow Effects 0.000 description 1
• 210000000544 articulatio talocruralis Anatomy 0.000 description 1
• 230000003143 atherosclerotic effect Effects 0.000 description 1
• 230000003305 autocrine Effects 0.000 description 1
• 210000001841 basilar artery Anatomy 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
• 238000005842 biochemical reaction Methods 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 230000014461 bone development Effects 0.000 description 1
• 230000010072 bone remodeling Effects 0.000 description 1
• KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
• 210000004958 brain cell Anatomy 0.000 description 1
• 230000006931 brain damage Effects 0.000 description 1
• 231100000874 brain damage Toxicity 0.000 description 1
• 230000003925 brain function Effects 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 238000004422 calculation algorithm Methods 0.000 description 1
• 239000012830 cancer therapeutic Substances 0.000 description 1
• 210000000234 capsid Anatomy 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 238000013184 cardiac magnetic resonance imaging Methods 0.000 description 1
• 210000001168 carotid artery common Anatomy 0.000 description 1
• 210000004004 carotid artery internal Anatomy 0.000 description 1
• 208000006170 carotid stenosis Diseases 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 108020001778 catalytic domains Proteins 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 230000000453 cell autonomous effect Effects 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 210000005056 cell body Anatomy 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 230000011712 cell development Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 210000003855 cell nucleus Anatomy 0.000 description 1
• 230000009134 cell regulation Effects 0.000 description 1
• 230000010307 cell transformation Effects 0.000 description 1
• 230000004715 cellular signal transduction Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 230000004637 cellular stress Effects 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 150000005829 chemical entities Chemical class 0.000 description 1
• 238000001311 chemical methods and process Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 229940044683 chemotherapy drug Drugs 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 210000000275 circle of willis Anatomy 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
• 229960003009 clopidogrel Drugs 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• 230000009137 competitive binding Effects 0.000 description 1
• 238000000205 computational method Methods 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 210000004087 cornea Anatomy 0.000 description 1
• 208000002528 coronary thrombosis Diseases 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 238000006880 cross-coupling reaction Methods 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 210000000172 cytosol Anatomy 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000030609 dephosphorylation Effects 0.000 description 1
• 238000006209 dephosphorylation reaction Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 125000004663 dialkyl amino group Chemical group 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
• 229960002768 dipyridamole Drugs 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 230000009429 distress Effects 0.000 description 1
• 230000007783 downstream signaling Effects 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 238000002651 drug therapy Methods 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 210000005069 ears Anatomy 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 238000005265 energy consumption Methods 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 229960000980 entecavir Drugs 0.000 description 1
• YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 238000001952 enzyme assay Methods 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 229940074057 epivir hbv Drugs 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• 125000004185 ester group Chemical group 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• 235000013861 fat-free Nutrition 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 210000002683 foot Anatomy 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 230000014101 glucose homeostasis Effects 0.000 description 1
• 230000009422 growth inhibiting effect Effects 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 230000002008 hemorrhagic effect Effects 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 230000005745 host immune response Effects 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• 230000037417 hyperactivation Effects 0.000 description 1
• 208000018875 hypoxemia Diseases 0.000 description 1
• 108091008915 immune receptors Proteins 0.000 description 1
• 102000027596 immune receptors Human genes 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 238000005470 impregnation Methods 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 108091006086 inhibitor proteins Proteins 0.000 description 1
• 238000013101 initial test Methods 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 230000009878 intermolecular interaction Effects 0.000 description 1
• 230000004068 intracellular signaling Effects 0.000 description 1
• 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
• 201000007272 intracranial sinus thrombosis Diseases 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 229960001627 lamivudine Drugs 0.000 description 1
• 108010051044 lanoteplase Proteins 0.000 description 1
• 229950010645 lanoteplase Drugs 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 230000021633 leukocyte mediated immunity Effects 0.000 description 1
• 150000007517 lewis acids Chemical class 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 230000037356 lipid metabolism Effects 0.000 description 1
• 230000004130 lipolysis Effects 0.000 description 1
• 238000005567 liquid scintillation counting Methods 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 235000021266 loss of appetite Nutrition 0.000 description 1
• 208000019017 loss of appetite Diseases 0.000 description 1
• 231100000053 low toxicity Toxicity 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 238000007433 macroscopic evaluation Methods 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 239000004579 marble Substances 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 102000006240 membrane receptors Human genes 0.000 description 1
• 108020004084 membrane receptors Proteins 0.000 description 1
• 230000037323 metabolic rate Effects 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 239000000203 mixture Substances 0.000 description 1
• 108091005601 modified peptides Proteins 0.000 description 1
• 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 230000004899 motility Effects 0.000 description 1
• 210000001721 multinucleated osteoclast Anatomy 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• UTWYCVYPCQKRDR-UHFFFAOYSA-N n-methyl-n-phenylhydroxylamine Chemical compound CN(O)C1=CC=CC=C1 UTWYCVYPCQKRDR-UHFFFAOYSA-N 0.000 description 1
• HUMMCEUVDBVXTQ-UHFFFAOYSA-N naphthalen-1-ylboronic acid Chemical compound C1=CC=C2C(B(O)O)=CC=CC2=C1 HUMMCEUVDBVXTQ-UHFFFAOYSA-N 0.000 description 1
• KPTRDYONBVUWPD-UHFFFAOYSA-N naphthalen-2-ylboronic acid Chemical compound C1=CC=CC2=CC(B(O)O)=CC=C21 KPTRDYONBVUWPD-UHFFFAOYSA-N 0.000 description 1
• 150000002790 naphthalenes Chemical class 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
• 238000010984 neurological examination Methods 0.000 description 1
• 231100000878 neurological injury Toxicity 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
• 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 230000036963 noncompetitive effect Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 229940005483 opioid analgesics Drugs 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 150000002926 oxygen Chemical class 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000009054 pathological process Effects 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 208000028169 periodontal disease Diseases 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 150000003916 phosphatidylinositol 3,4,5-trisphosphates Chemical class 0.000 description 1
• 150000003009 phosphonic acids Chemical group 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
• 230000010287 polarization Effects 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 230000006659 positive regulation of apoptotic process Effects 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 108020003519 protein disulfide isomerase Proteins 0.000 description 1
• 230000009822 protein phosphorylation Effects 0.000 description 1
• 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 description 1
• 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• 208000005333 pulmonary edema Diseases 0.000 description 1
• 235000021251 pulses Nutrition 0.000 description 1
• 238000010926 purge Methods 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• 230000000171 quenching effect Effects 0.000 description 1
• 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000010666 regulation of catalytic activity Effects 0.000 description 1
• 230000008521 reorganization Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 229960002917 reteplase Drugs 0.000 description 1
• 108010051412 reteplase Proteins 0.000 description 1
• 108010004093 retinal S antigen peptide M Proteins 0.000 description 1
• 201000011195 retinal edema Diseases 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 238000009666 routine test Methods 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 238000001878 scanning electron micrograph Methods 0.000 description 1
• 238000007789 sealing Methods 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 230000035807 sensation Effects 0.000 description 1
• 235000019615 sensations Nutrition 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 230000000405 serological effect Effects 0.000 description 1
• 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
• 208000018316 severe headache Diseases 0.000 description 1
• 208000013220 shortness of breath Diseases 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 239000000243 solution Substances 0.000 description 1
• 238000007614 solvation Methods 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 238000012289 standard assay Methods 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 230000036262 stenosis Effects 0.000 description 1
• 208000037804 stenosis Diseases 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 229960005202 streptokinase Drugs 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 210000002301 subretinal fluid Anatomy 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 238000002907 substructure search Methods 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 150000003460 sulfonic acids Chemical class 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 230000035900 sweating Effects 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• 230000019432 tissue death Effects 0.000 description 1
• 208000037816 tissue injury Diseases 0.000 description 1
• 238000003325 tomography Methods 0.000 description 1
• 238000006257 total synthesis reaction Methods 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 229960005356 urokinase Drugs 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 230000006459 vascular development Effects 0.000 description 1
• 210000003556 vascular endothelial cell Anatomy 0.000 description 1
• 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
• 229960005080 warfarin Drugs 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 230000037303 wrinkles Effects 0.000 description 1
• 230000031143 xenobiotic glucuronidation Effects 0.000 description 1